First‐in‐Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers

• Published in: Clinical pharmacology in drug development Vol. 8; no. 8; pp. 1088 - 1099
• Main Authors: Okour, Malek, Gress, Angela, Zhu, Xinyi, Rieman, David, Lickliter, Jason D., Brigandi, Richard A.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2019
• Subjects: Biosynthesis; Clinical trials; DGAT inhibitor; Drug therapy; Enzymes; GSK3008356; healthy volunteers; Inhibitor drugs; Pharmacokinetics; Pharmacology; safety; pharmacokinetics; DGAT inhibitor; GSK3008356; safety; healthy volunteers

Diacylglycerol acyltransferase (DGAT) enzymes are involved in triglyceride (TG) biosynthesis. GSK3008356 is a potent and selective DGAT1 inhibitor that was administered orally in a 2‐part study as double‐blind, randomized, placebo‐controlled single doses (SDs) and repeat doses (RDs) in healthy subje...